|Group:||Group I (dsDNA)|
The BK virus is a member of the polyomavirus family. Past infection with the BK virus is widespread, but significant consequences of infection are uncommon, with the exception of the immunocompromised and the immunosuppressed.
Micrograph showing a polyomavirus infected cell — large (blue) cell below-center-left. Urine cytology specimen.
|Classification and external resources|
The BK virus was first isolated in 1971 from the urine of a renal transplant patient, initials B.K. The BK virus is similar to another virus called the JC virus (JCV), since their genomes share 75% sequence similarity. Both of these viruses can be identified and differentiated from each other by carrying out serological tests using specific antibodies or by using a PCR based genotyping approach.
The BK virus rarely causes disease; many people who are infected with this virus are asymptomatic. If symptoms do appear, they tend to be mild: respiratory infection or fever. These are known as primary BK infections.
The virus then disseminates to the kidneys and urinary tract where it persists for the life of the individual. It is thought that up to 80% of the population contains a latent form of this virus, which remains latent until the body undergoes some form of immunosuppression. Typically, this is in the setting of kidney transplantation or multi-organ transplantation. Presentation in these immunocompromised individuals is much more severe. Clinical manifestations include renal dysfunction (seen by a progressive rise in serum creatinine), and an abnormal urinalysis revealing renal tubular cells and inflammatory cells.
It is not known how this virus is transmitted. It is known, however, that the virus is spread from person to person, and not from an animal source. It has been suggested that this virus may be transmitted through respiratory fluids or urine, since infected individuals periodically excrete virus in the urine. A survey of 400 healthy blood donors was reported as showing that 82% were positive for IgG against BK virus.
In some renal transplant patients, the necessary use of immunosuppressive drugs has the side-effect of allowing the virus to replicate within the graft, a disease called BK nephropathy. From 1–10% of renal transplant patients progress to BK virus associated nephropathy (BKVAN) and up to 80% of these patients lose their grafts. The onset of nephritis can occur as early as several days post-transplant to as late as 5 years.
The cornerstone of therapy is reduction in immunosuppression. A recent surge in BKVAN correlates with use of potent immunosuppressant drugs, such as tacrolimus and mycophenolate mofetil (MMF). Studies have not shown any correlation between BKVAN and a single immunosuppressive agent but rather the overall immunosuppressive load.
- No guidelines or drug levels and doses exist for proper reduction of immunosuppressants in BKVAN
- Most common methods:
- Withdrawal of MMF or tacrolimus
- Replacement of tacrolimus by cyclosporine
- Overall reduction of immunosuppressive load
- Some cyclosporine trough levels reported to be reduced to 100–150 ng/ml and tacrolimus levels reduced to 3–5 ng/ml
- Retrospective analysis of 67 patients concluded graft survival was similar between reduction and discontinuation of agents.
- Single center study showed renal allografts were preserved in 8/8 individuals managed with reduction in immunosuppression while graft loss occurred in 8/12 patients treated with an increase in therapy for what was thought to be organ rejection.
Other therapeutic options include Leflunomide, Cidofovir, IVIG, and the fluoroquinolones. Leflunomide, a pyrimidine synthesis inhibitor is now generally accepted as the second treatment option behind reduction of immunosuppression.
Leflunomide in BKVAN
The rationale behind using leflunomide in BKVAN comes from its combined immunosuppressive and antiviral properties. Two studies consisting of 26 and 17 patients who developed BKVAN on a three-drug regimen of tacrolimus, MMF, and steroids had their MMF replaced with leflunomide 20–60 mg daily. 84 and 88% of patients, respectively had clearance or a progressive reduction in viral load and a stabilization or improvement of graft function (7). In a study conducted by Teschner et al. in 2009, 12/13 patients who had their MMF exchanged with leflunomide cleared the virus by 109 days. In a case series, there was improvement or stabilization in 23/26 patients with BKVAN after switching MMF to leflunomide.
There are no dosing guidelines for leflunomide in BKVAN. Patient to patient variability has made dosing and monitoring of leflunomide extremely difficult.
- Study of 26 and 17 patients were dosed between 20 mg/day and 60 mg/day with trough levels of 50—100 µg/ml. Failure was seen in patients with leflunomide plasma levels < 40 µg/ml.
- One study of 21 patients found that low levels (< 40 µg/ml) and high levels (> 40 µg/ml) had similar effects on the rate of viral clearance. Those with higher levels had more adverse events (hematologic, hepatic).
- In the study by Teschner et al., dosages and drug concentration showed no correlation with substantial variation from person to person.
- In the Teschner study, low drug concentrations were associated with decrease in viral load. This makes it difficult to determine whether or not reduction of viral load or addition of leflunomide was the cause for viral clearance.
Other treatment options
- Quinolone antibiotics: Ciprofloxacin (Cipro) was shown to significantly lower viral loads but no data on survival and graft loss exist.
- Intravenous immunoglobulin (IVIG) has use in the treatment of infection and allograft rejection – hard to distinguish[clarification needed]
- Cidofovir has limited data and is highly nephrotoxic.
Prediction of BKVAN after kidney transplantation
A recent study from The Cleveland Clinic reported that BK viremia load > 185 000 copies/ml at the time of first positive BKV diagnosis - to be the strongest predictor for BKVAN (97% specificity and 75% sensitivity). In addition the BKV peak viral loads in blood reaching 223 000 copies/ml at any time was found to be predictive for BKVAN (91% specificity and 88% sensitivity) .
- Gardner SD, Field AM, Coleman DV, Hulme B (June 1971). "New human papovavirus (B.K.) isolated from urine after renal transplantation". Lancet 1 (7712): 1253–7. PMID 4104714.
- Gupta G, Shapiro R, Thai N, Randhawa PS, Vats A (August 2006). "Low incidence of BK virus nephropathy after simultaneous kidney pancreas transplantation". Transplantation 82 (3): 382–8. doi:10.1097/01.tp.0000228899.05501.a7. PMID 16906037.
- Egli A; Infanti L; Dumoulin A et al. (2009). "Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors". J Infect Dis 199 (6): 837–46. doi:10.1086/597126. PMID 19434930.
- Fishman, J. A. (2002). "BK Virus Nephropathy — Polyomavirus Adding Insult to Injury". New England Journal of Medicine 347 (7): 527–530. doi:10.1056/NEJMe020076. PMID 12181409.
- Bista, BR; Ishwad, C; Wadowsky, RM; Manna, P; Randhawa, PS; Gupta, G; Adhikari, M; Tyagi, R; Gasper, G (2007). "Development of a Loop-Mediated Isothermal Amplification Assay for Rapid Detection of BK Virus". Journal of clinical microbiology 45 (5): 1581–7. doi:10.1128/JCM.01024-06. PMC 1865893. PMID 17314224.
- Elfadawy, NS; Flechner, SM; Xiaobo, L; Schold, J; Tian, D; Srinivas, TR; Poggio, E; Fatica, R; Avery, R; Mosaad, SB (2013). "The impact of surveillance and rapid reduction in immunosuppression to control BK virus-related graft injury in kidney transplantation". Transplant International 26 (8): 822–32. doi:10.1111/tri.12134. PMID 23763289.
- Overview of the BK virus
- MicrobiologyBytes: Polyomaviruses
- Reploeg MD, Storch GA, Clifford DB (July 2001). "Bk virus: a clinical review". Clin. Infect. Dis. 33 (2): 191–202. doi:10.1086/321813. PMID 11418879.
- "BK virus". Am. J. Transplant. 4 (Suppl 10): 89–91. November 2004. doi:10.1111/j.1600-6135.2004.00730.x. PMID 15504220.
- Blanckaert K, De Vriese AS (December 2006). "Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients". Nephrol. Dial. Transplant. 21 (12): 3364–7. doi:10.1093/ndt/gfl404. PMID 16998219.